Patents Assigned to AstraZeneca AB
  • Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
    Patent number: 10882858
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising to substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
  • Inhibitors of phosphatidylinositol 3-kinase gamma
    Patent number: 10858355
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Mickael Mogemark, Nils Pemberton, Jens Petersen, Matthew Perry, Konstantinos Karabelas, Pavol Zlatoidsky, Rhona Cox, Christian Tyrchan
  • Inhalation device for powdered drugs
    Patent number: 10828433
    Abstract: The invention refers to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when actuated by the patient.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: November 10, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Martin Herder, Gerhard Ludanek, Ingo Mett, Joachim Schmidt
  • C-anilinoquinazoline compounds and their use in treating cancer
    Patent number: 10829479
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: November 10, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith, Tudor Grecu
  • NMDA antagonist prodrugs
    Patent number: 10815199
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: October 27, 2020
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA
    Publication number: 20200308164
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) and phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: October 1, 2020
    Applicant: AstraZeneca AB
    Inventors: Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
  • NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
    Publication number: 20200299289
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (P13K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: March 9, 2017
    Publication date: September 24, 2020
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
    Patent number: 10772890
    Abstract: The present invention relates to the use of myeloperoxidase inhibitors (MPO) inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 15, 2020
    Assignee: AstraZeneca AB
    Inventors: Hakan Eriksson, Werner Poewe
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10766905
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Orally disintegrating tablets
    Patent number: 10729655
    Abstract: The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 4, 2020
    Assignee: AstraZeneca AB
    Inventors: Farhan Abdel Karim Mohammad Al Husban, Lars Håkan Christer Glad, Jenny Malin Christina Hallstein, Andrea Jane Moir, Michael Peter Thompson
  • Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
    Publication number: 20200237758
    Abstract: The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancer involving a gain of copy number of NRAS gene.
    Type: Application
    Filed: April 2, 2015
    Publication date: July 30, 2020
    Applicant: AstraZeneca AB
    Inventors: Darren Anthony, Edward Cross, Catherine Anne Eberlein
  • Chemical compounds
    Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Arginase Inhibitors and Methods of Use
    Publication number: 20200223871
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Application
    Filed: August 22, 2019
    Publication date: July 16, 2020
    Applicants: AstraZeneca AB, The Trustees of the University of Pennsylvania
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide
    Patent number: 10689387
    Abstract: A crystalline form of (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide, pharmaceutical compositions containing it and its use in the prevention or treatment of cardiovascular diseases.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 23, 2020
    Assignee: AstraZeneca AB
    Inventor: Anna Matilda Angelica Pettersen
  • NOVEL COMPOUNDS
    Publication number: 20200181084
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: November 25, 2019
    Publication date: June 11, 2020
    Applicant: AstraZeneca AB
    Inventors: Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG, Sarah LEVER
  • Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors
    Patent number: 10669245
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: June 2, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20200157113
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: October 30, 2019
    Publication date: May 21, 2020
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof BRODDEFALK, Hans Fredrik EMTENÂS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
  • Protein kinase B inhibitors
    Patent number: 10654855
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 19, 2020
    Assignee: AstraZeneca AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Chemical compounds
    Patent number: 10597405
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 24, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
  • Selective estrogen receptor down-regulators
    Patent number: 10590132
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 17, 2020
    Assignee: AstraZeneca AB
    Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang